• BUSINESS
    • FINANCE
    • LEGAL
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • HEALTHCARE & PHARMACEUTICALS
    • MEDIA & TELECOM
    • AEROSPACE AND DEFENSE
    • ENERGY
  • MARKETS
    • EUROPEAN MARKETS
    • ASIAN MARKETS
    • U.S. MARKETS
    • COMMODITIES
    • EMERGING MARKETS
    • DEALS
    • RATES & BONDS
  • WORLD
    • UNITED STATES
    • EUROPE
    • UNITED KINGDOM
    • ASIA PACIFIC
    • MIDDLE EAST
    • AFRICA
    • CHINA
    • INDIA
    • JAPAN
    • AMERICAS
    • FRANCE
    • GERMANY
  • POLITICS
    • GOVERNMENT
    • UNITED STATES
    • US SUPREME COURT
  • TECH
    • ARTIFICIAL INTELLIGENCE
    • CYBERSECURITY
    • SPACE
    • DISRUPTED
  • COMMENTARY
  • BREAKINGVIEWS
    • BREAKINGVIEWS PREDICTIONS
  • MONEY
    • WEALTH
    • FUNDS
    • ETFS
  • LIFE
    • LIFESTYLE
    • SPORTS
    • SCIENCE
  • SECTORS
    • ENERGY
    • HEALTHCARE
    • MEDIA & TELECOM
    • SUSTAINABILITY
    • ENVIRONMENT
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • AEROSPACE AND DEFENSE
FinanceTime
  • August 20th, 2026

FinanceTimeFinancetime

  • BUSINESS
    • FINANCE
    • LEGAL
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • HEALTHCARE & PHARMACEUTICALS
    • MEDIA & TELECOM
    • AEROSPACE AND DEFENSE
    • ENERGY
  • MARKETS
    • EUROPEAN MARKETS
    • ASIAN MARKETS
    • U.S. MARKETS
    • COMMODITIES
    • EMERGING MARKETS
    • DEALS
    • RATES & BONDS
  • WORLD
    • UNITED STATES
    • EUROPE
    • UNITED KINGDOM
    • ASIA PACIFIC
    • MIDDLE EAST
    • AFRICA
    • CHINA
    • INDIA
    • JAPAN
    • AMERICAS
    • FRANCE
    • GERMANY
  • POLITICS
    • GOVERNMENT
    • UNITED STATES
    • US SUPREME COURT
  • TECH
    • ARTIFICIAL INTELLIGENCE
    • CYBERSECURITY
    • SPACE
    • DISRUPTED
  • COMMENTARY
  • BREAKINGVIEWS
    • BREAKINGVIEWS PREDICTIONS
  • MONEY
    • WEALTH
    • FUNDS
    • ETFS
  • LIFE
    • LIFESTYLE
    • SPORTS
    • SCIENCE
  • SECTORS
    • ENERGY
    • HEALTHCARE
    • MEDIA & TELECOM
    • SUSTAINABILITY
    • ENVIRONMENT
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • AEROSPACE AND DEFENSE
Home
Business
Healthcare & Pharmaceuticals

Michigan confirms human case of rare mosquito-borne disease

August 19th, 2026 | 18:51 PM BUSINESS Healthcare & Pharmaceuticals 2

Facebook Twitter Google+ LinkedIn Pinterest

Worth reading...

Multistate salmonella infections climb to 431, US CDC says
Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder
US FDA approves Regeneron's rare bone disorder drug
West Nile virus outbreak kills four in North Macedonia 
By Reuters

The Michigan health department on Wednesday confirmed a locally acquired case of eastern equine encephalitis, ​a rare mosquito-borne disease.

The patient, a resident ‌of Roscommon County, is the first human case of the disease reported in Michigan since 2021, the state health ​department said, adding that no animal Eastern ​equine encephalitis activity was detected in Michigan prior to ⁠this.

The rare but serious viral disease is spread to people by ​the bite of an infected mosquito. Only a few ​human cases are reported each year in the United States.

"EEE is one of the most dangerous mosquito-borne diseases in ​the U.S., with a 30% fatality rate among ​people who become ill," Michigan's Chief Medical Executive Natasha Bagdasarian said.

Patients with EEE may ‌experience ⁠fever, headache, chills and nausea. In some cases, symptoms may progress to inflammation of the brain, signaled by disorientation, seizures and coma.

Additional mosquito trapping and ​testing is ​underway in ⁠Roscommon County to assess the level of risk in the area, the Michigan ​Department of Health and Human Services ​said.

The state health ⁠department urged residents to take precautions against mosquito bites, and said it will continue to monitor for ⁠signs ​of EEE in humans, mosquitos, ​domestic animals and wildlife along with state and local authorities.

  • Topic
  • HEALTH
  • USA/RARE DISEASE
Facebook Twitter Google+ LinkedIn Pinterest
Next article Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder
Previous article US FDA approves Regeneron's rare bone disorder drug

Related Posts

Healthcare & Pharmaceuticals
August 19th, 2026

Multistate salmonella infections climb to 431, US CDC says

Healthcare & Pharmaceuticals
August 19th, 2026

Ultragenyx's gene therapy wins first FDA approval for rare metabolic dis...

Healthcare & Pharmaceuticals
August 19th, 2026

US FDA approves Regeneron's rare bone disorder drug

Healthcare & Pharmaceuticals
August 19th, 2026

West Nile virus outbreak kills four in North Macedonia 

Healthcare & Pharmaceuticals
August 19th, 2026

Moderna shares double as cancer vaccine data rekindles investor hopes

Healthcare & Pharmaceuticals
August 19th, 2026

China's top drugmaker Hengrui sees profit growth squeezed by bulk-buying...

The Wire
Aug 20th 1 h ago
Investigates

In China, rocket launches fuel tourism and space-age dreams

Aug 19th 2 h ago
Asia Pacific

Japan exports rise 23.2% year/year in July

Aug 19th 2 h ago
Baseball

D-backs score twice in 10th, salvage series finale at Red S...

Aug 19th 3 h ago
Government

US tells schools not to alter discipline policies to reduce...

Aug 19th 3 h ago
Transactional

China tax crackdown forces wealthy investors to assess thei...

TRENDING ON FINANCETIME
Aug 19th, 2026 Tennis

Paul ousts top seed Zverev to reach Cincinnati quarter-finals

Aug 19th, 2026 Litigation

AIA Group's first-half new business value rises 10%

Aug 19th, 2026 Energy

Brazil's largest thermal power plant shut down after equipment failure

Aug 19th, 2026 United Kingdom

Key moments in Prince Harry and Meghan's six years in California

Aug 19th, 2026 Sports

Orioles reinstate C Samuel Basallo (shoulder) to active roster

Markets-Sectors
ENERGY -0.16%
FINANCIALS -0.62%

  • BUSINESS
  • MARKETS
  • WORLD
  • POLITICS
  • TECH
  • COMMENTARY
  • BREAKINGVIEWS
  • MONEY
  • LIFE
  • SECTORS
  • Back to top
FinanceTime
FinanceTime

World Business & Financial News, Breaking US & International News

Additional Services
  • Privacy-Policy
  • Terms and Conditions
© Financetime.org 2026. All rights reserved. Hosted by LeadsDeposit.com
Produced by C-iT